The urge to merge continues to surge. The Supreme Court’s decision in King v. Burwell, which for now halts legal challenges to the ACA, seems to have given insurers the certainty they need to buy and/or join. Deals proposed over the summer amount to $100 billion. Anti-trust issues are in play, however.
Even as the law withstands legal challenges and signs up millions of uninsured, there’s still concern that “young invincibles” will not participate enough to help dilute the risk. Perhaps more subsidies and the introduction of a “copper plan” would reinforce the foundation. Affordability remains an issue for many.
Government and other surveys are showing that the number of Americans without health insurance is dwindling, with credit going to the expansion of Medicaid and the ACA insurance exchanges.
Narrow networks mean lower premiums. Now, state insurance commissioners are wrestling with how they should be regulated so that insurers stay solvent and consumers are protected.
The NIH would get a $9 billion shot in the arm, but some fear the FDA provisions will mean lax oversight of drugs and devices.
Brace yourself for astronomically priced injections. One on track for U.S. approval looks to treat a rare form of retinal disease.